OPKO Health Inc.

Company Overview

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. Its pharmaceutical arm features Rayaldee, FDA-approved for treating secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency, as well as Somatrogon (hGH-CTP), approved in over 50 markets for treating growth disturbance in children and adolescents due to growth hormone deficiency.

In May 2022, OPKO acquired ModeX Therapeutics, Inc., focusing on multi-specific immune therapies for cancer and infectious diseases, enhancing its pharmaceutical pipeline.

BioReference Health, LLC, owned by OPKO Health, Inc., is a biopharmaceutical and diagnostics company. Based in Elmwood Park, New Jersey, BioReference has 10 labs nationwide, is in-network with major health plans, and conducts over 9 million tests yearly.

The diagnostics business, operated through BioReference Health, LLC, offers the 4Kscore prostate cancer test and a wide range of laboratory testing services across various states, catering to physicians, hospitals, clinics, and other healthcare facilities.

Financial Highlights (FY 2024)

Company's Business Segments

• Diagnostics : This segment primarily consists of BioReference's clinical laboratory operations.
• Pharmaceuticals : The company currently has two commercial-stage pharmaceutical products and several compounds and technologies in various stages of research and development for a broad range of indications and conditions.